Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)



Status:Recruiting
Conditions:Allergy, Allergy, Neurology
Therapuetic Areas:Neurology, Otolaryngology
Healthy:No
Age Range:6 - 17
Updated:1/9/2019
Start Date:October 3, 2018
End Date:March 9, 2021
Contact:Clinical Trials Administrator
Email:clinicaltrials@regeneron.com
Phone:844-734-6643

Use our guide to learn which trials are right for you!

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo
improves desensitization at the completion of up-dosing, defined as an increase in the
proportion of participants who pass a double-blind placebo-controlled food challenge (DBPCFC)
at week 28.

Secondary objectives are:

- To assess whether dupilumab as adjunct to AR101 compared to placebo improves
desensitization at the completion of up-dosing, defined as an increase in the cumulative
tolerated dose (log transformed) of peanut protein during a DBPCFC at week 28

- To assess whether dupilumab as (indefinite [continuously]) adjunct to AR101 compared to
placebo maintains desensitization, defined as an increase in the proportion of
participants who pass a DBPCFC at week 52

- To assess whether dupilumab as (limited [previously]) adjunct to AR101 compared to
placebo maintains desensitization, defined as an increase in the proportion of
participants who pass a DBPCFC at week 52

- To evaluate the safety and tolerability of dupilumab as adjunct to AR101 compared to
placebo

- To assess the effect of dupilumab (compared to placebo) as adjunct to AR101 on the
change in peanut-specific Immunoglobulin E (sIgE), Immunoglobulin G4 (IgG4), and
peanut-specific IgG4/IgE ratio

- To assess if dupilumab increases the tolerability of AR101 as measured by the daily
symptoms (e-diary) during the up-dosing phase


Key Inclusion Criteria:

- Experience dose-limiting symptoms at or before the challenge dose of peanut protein on
screening and not experiencing dose-limiting symptoms to placebo

- Serum Immunoglobulin E (IgE) to peanut of ≥24 kUA/L and/or a skin prick test (SPT) to
peanut ≥10 mm compared to a negative control

- Participants/caregivers must be trained on the proper use of the epinephrine
autoinjector device to be allowed to enroll in the study

- Participants with other known food allergies must agree to eliminate these other food
items from their diet so as not to confound the safety and efficacy data from the
study

Key Exclusion Criteria:

- History of other chronic disease (other than asthma, Atopic Dermatitis (AD), or
allergic rhinitis) requiring therapy (eg, heart disease, diabetes, hypertension) that
would represent a risk to participant's health or safety in this study or ability to
comply with study protocol

- History of frequent or recent severe, life-threatening episode of anaphylaxis or
anaphylactic shock

- History of eosinophilic Gastrointestinal (GI) disease

- Asthma at time of enrollment with any of the following:

- Forced Expiratory Volume 1 Second (FEV1) <80% of predicted or ratio of FEV1 to
forced vital capacity (FEV1/FVC) <75% of predicted with or without controller
medications

- Inhaled corticosteroids (ICS) dosing of daily fluticasone (or equivalent ICS
based on NHLBI dosing chart)

- One hospitalization in the past year for asthma

- Emergency room visit for asthma within 6 months prior to screening

- Use of systemic corticosteroids within 2 months prior to screening

- Use of other investigation form of allergen immunotherapy or immunomodulatory therapy
within 3 months prior to screening

- Use of any agents known or likely to interact with epinephrine (eg, beta-blockers,
angiotensin converting enzyme-inhibitors, tri-cyclic antidepressants, or other drugs),
within 3 weeks prior to screening

- Allergy to oat (placebo in DBPCFC)

Note: Other protocol Inclusion/Exclusion Criteria apply
We found this trial at
8
sites
Ypsilanti, Michigan 48197
?
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Birmingham, Alabama
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Marietta, Georgia 30144
?
mi
from
Marietta, GA
Click here to add this to my saved trials
Minneapolis, Minnesota
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Mission Viejo, California 92691
?
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Ocean Township, New Jersey 07712
?
mi
from
Ocean Township, NJ
Click here to add this to my saved trials
Rolling Hills Estates, California 90274
?
mi
from
Rolling Hills Estates, CA
Click here to add this to my saved trials
Tampa, Florida
?
mi
from
Tampa, FL
Click here to add this to my saved trials